Hudson Bay Capital Management LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hudson Bay Capital Management LP reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 48.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,006 shares of the biopharmaceutical company's stock after selling 14,346 shares during the period. Hudson Bay Capital Management LP's holdings in Regeneron Pharmaceuticals were worth $10,689,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of REGN. Capital International Investors grew its holdings in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after buying an additional 1,390,534 shares during the last quarter. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $802,036,000. Price T Rowe Associates Inc. MD raised its stake in shares of Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after purchasing an additional 810,144 shares during the last quarter. Amundi raised its position in Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after buying an additional 487,489 shares during the last quarter. Finally, Loomis Sayles & Co. L P lifted its stake in Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after acquiring an additional 393,997 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on REGN. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price target on the stock. Guggenheim decreased their target price on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. JPMorgan Chase & Co. reduced their price target on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. Finally, Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $890.60.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $13.63 on Thursday, reaching $584.99. The company's stock had a trading volume of 1,301,765 shares, compared to its average volume of 785,438. The company has a market capitalization of $63.95 billion, a price-to-earnings ratio of 15.28, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The stock's fifty day simple moving average is $605.64 and its 200-day simple moving average is $689.30. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $520.50 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter last year, the firm earned $9.55 earnings per share. The business's quarterly revenue was down 3.7% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.60%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.